文献速递乳腺癌

欧洲癌症研究与治疗组织10041/BIG 03-04 MINDACT试验中乳腺癌局部区域复发:包括70基因特征在内的危险因素分析

Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature.
PubMed 文献 · J Clin Oncol · 2024-01-19

该研究为MINDACT试验的探索性亚组分析,评估70基因风险评分与早期乳腺癌保乳术后局部区域复发(LRR)的关系。5,470例保乳患者中98%接受放疗,8年LRR累积发生率为3.2%(95%CI 2.7-3.7),低风险70基因特征患者为2.7%(95%CI 2.1-3.3)。多变量模型中70基因特征并非LRR的独立预测因素。

要点

  • 保乳术后8年LRR累积发生率为3.2%(95%CI 2.7-3.7),低风险70基因特征患者为2.7%(95%CI 2.1-3.3)。
  • 单变量分析中70基因特征与LRR相关,但多变量模型中未显示独立预测作用。
  • 多变量模型中辅助内分泌治疗与LRR显著相关,肿瘤大小和分级关联程度较弱。

核心结论

  • MINDACT试验的探索性分析估计保乳术后8年LRR发生率较低,为3.2%。
  • 70基因特征并非LRR的独立预测因素,可能因为观察到的events数量少,目前不能用于LRR相关的临床决策。
  • 整体较低的events数量为设计局部治疗降阶梯试验提供了机会。

研究设计与样本

  • 欧洲癌症研究与治疗组织10041/BIG 03-04 MINDACT试验的探索性亚组分析。
  • 纳入已知临床和基因组70基因风险评分检测结果并接受保乳手术的女性。
  • 6,693例入组患者中5,470例(81.7%)接受保乳手术,其中98%接受放疗。
  • 主要终点为8年LRR,采用累积发生率估计,远处转移和死亡视为竞争风险。

主要发现

  • 8年随访时189例患者发生LRR,8年累积发生率为3.2%(95%CI 2.7-3.7)。
  • 低风险70基因特征患者8年LRR发生率为2.7%(95%CI 2.1-3.3)。
  • 经化疗校正的单变量分析中,12个变量中有5个与LRR相关,包括70基因特征。
  • 多变量模型中,辅助内分泌治疗与LRR保持显著相关,肿瘤大小和分级的关联程度较弱。

临床怎么用

  • 原文结论指出70基因特征目前不能用于LRR相关的临床决策。
  • 原文结论指出整体较低的events数量为设计局部治疗降阶梯试验提供了机会。

局限性

  • 原文指出70基因特征未显示独立预测作用可能因为观察到的events数量少。
  • 原文为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A number of studies are currently investigating de-escalation of radiation therapy in patients with a low risk of in-breast relapses on the basis of clinicopathologic factors and molecular tests. We evaluated whether 70-gene risk score is associated with risk of locoregional recurrence (LRR) and estimated 8-year cumulative incidences for LRR in patients with early-stage breast cancer treated with breast conservation. METHODS: In this exploratory substudy of European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT trial, we evaluated women with a known clinical and genomic 70-gene risk score test result and who had breast-conserving surgery (BCS). The primary end point was LRR at 8 years, estimated by cumulative incidences. Distant metastasis and death were considered competing risks. RESULTS: Among 6,693 enrolled patients, 5,470 (81.7%) underwent BCS, of whom 98% received radiotherapy. At 8-year follow-up, 189 patients experienced a LRR, resulting in an 8-year cumulative incidence of 3.2% (95% CI, 2.7 to 3.7). In patients with a low-risk 70-gene signature, the 8-year LRR incidence was 2.7% (95% CI, 2.1 to 3.3). In univariable analysis, adjusted for chemotherapy, five of 12 variables were associated with LRR, including the 70-gene signature. In multivariable modeling, adjuvant endocrine therapy and to a lesser extent tumor size and grade remained significantly associated with LRR. CONCLUSION: This exploratory analysis of the MINDACT trial estimated an 8-year low LRR rate of 3.2% after BCS. The 70-gene signature was not independently predictive of LRR perhaps because of the low number of events observed and currently cannot be used in clinical decision making regarding LRR. The overall low number of events does provide an opportunity to design trials toward de-escalation of local therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Alaeikhanehshir S, Ajayi T, Duijnhoven FH, et al. Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature. J Clin Oncol. 2024. PMID: 38241603. doi:10.1200/JCO.22.02690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。